|
Samples from HCV Genotype-1 Patients Treated for 5 Days with TMC435 Monotherapy and Subsequently Re-treated with TMC435 in Combination with PegIFNα-2a/Ribavirin - slide talk
|
|
|
Reported by Jules Levin
O Lenz,1 L Vijgen,1 T Verbinnen,1 H van Marck,1 I Vandenbroucke,1 M Peeters,1 G De Smedt,1 K Simmen,1 G Fanning,1 H. Reesink,2 and G Picchio3
1Tibotec BVBA, Mechelen, Belgium; 2Academic Medical Center, Amsterdam, The Netherlands; 3Tibotec Inc., Yardley, PA, USA
![](../images/061410/061410-1/image002.gif)
![](../images/061410/061410-1/image004.gif)
![](../images/061410/061410-1/image006.gif)
![](../images/061410/061410-1/image008.gif)
![](../images/061410/061410-1/image010.gif)
![](../images/061410/061410-1/image012.gif)
![](../images/061410/061410-1/image014.gif)
![](../images/061410/061410-1/image016.gif)
![](../images/061410/061410-1/image018.gif)
|
|
|
|
|
|
|